Montelukast
- Generic Name
- Montelukast
- Brand Names
- Singulair
- Drug Type
- Small Molecule
- Chemical Formula
- C35H36ClNO3S
- CAS Number
- 158966-92-8
- Unique Ingredient Identifier
- MHM278SD3E
- Background
Montelukast was first approved for clinical use by the US FDA in 1998 as Merck's brand name Singulair. The medication is a member of the leukotriene receptor antagonist (LTRA) category of drugs. Although capable of demonstrating effectiveness, the use of such LTRAs like montelukast is typically in addition to or complementary with the use of inhaled corticos...
- Indication
Montelukast is indicated for:
...
- Associated Conditions
- Asthma, Exercise-Induced Bronchospasm, Perennial Allergic Rhinitis (PAR), Seasonal Allergic Rhinitis
- Associated Therapies
- -
Study of the Arachidonate 5-Lipoxygenase Enzyme in Affecting the Risk for Coronary Heart Disease
- First Posted Date
- 2006-09-22
- Last Posted Date
- 2012-07-23
- Lead Sponsor
- University of Florida
- Target Recruit Count
- 22
- Registration Number
- NCT00379808
- Locations
- 🇺🇸
University of Florida Family Practice Medical Group Clinic, Gainesville, Florida, United States
Effect of Montelukast on Experimentally-Induced RV16 Infection in Asthma
- First Posted Date
- 2006-08-01
- Last Posted Date
- 2018-03-13
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 25
- Registration Number
- NCT00359073
- Locations
- 🇺🇸
University of Wisconsin, Madison, Wisconsin, United States
Ramatroban/Montelukast Versus Montelukast/Placebo on the Early Allergic Reaction in Asthma Sensitive to House Dust Mite
- Conditions
- First Posted Date
- 2006-04-05
- Last Posted Date
- 2012-04-16
- Lead Sponsor
- Research Center Borstel
- Registration Number
- NCT00311051
- Locations
- 🇩🇪
Research Center Borstel, Borstel, Germany
Inflammatory Response to Anti Inflammatory Therapy in Children With Sleep Disordered Breathing
- Conditions
- First Posted Date
- 2006-03-07
- Last Posted Date
- 2008-05-21
- Lead Sponsor
- Soroka University Medical Center
- Target Recruit Count
- 50
- Registration Number
- NCT00299910
- Locations
- 🇮🇱
Pediatric Sleep Center, Soroka University Medical Center, Beer-Sheva, Israel
Study Of Patients With Allergic Rhinitis And Asthma
- Conditions
- First Posted Date
- 2006-02-27
- Last Posted Date
- 2016-10-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 600
- Registration Number
- NCT00296530
- Locations
- 🇺🇸
GSK Investigational Site, Charlottesville, Virginia, United States
Compare the Efficacy of Levocetirizine and Montelukast to Placebo in Reducing Seasonal Allergic Rhinitis (SAR) Symptoms in Ragweed Sensitive Subjects
- Conditions
- Interventions
- First Posted Date
- 2006-02-22
- Last Posted Date
- 2018-09-11
- Lead Sponsor
- UCB S.A. - Pharma Sector
- Target Recruit Count
- 418
- Registration Number
- NCT00295022
Study With GW274150 In Patients With Mild Asthma
- First Posted Date
- 2006-01-09
- Last Posted Date
- 2017-10-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 28
- Registration Number
- NCT00273013
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
Exercise Induced Bronchospasm in Children
- Conditions
- Interventions
- First Posted Date
- 2006-01-09
- Last Posted Date
- 2008-05-07
- Lead Sponsor
- University of New Mexico
- Target Recruit Count
- 13
- Registration Number
- NCT00273689
- Locations
- 🇺🇸
University of New Mexico, Albuquerque, New Mexico, United States
Evaluate the Potential of Montelukast to Prevent Nasal Symptomatology During Colds
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2020-11-18
- Lead Sponsor
- Deborah Gentile
- Target Recruit Count
- 84
- Registration Number
- NCT00189475
- Locations
- 🇺🇸
Allegheny General Hospital, Pittsburgh, Pennsylvania, United States
A Pilot Study to Evaluate the Efficacy of Montelukast in the Treatment of Acute Otitis Media (AOM) in Children
- Conditions
- Interventions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2020-11-18
- Lead Sponsor
- Deborah Gentile
- Target Recruit Count
- 99
- Registration Number
- NCT00189462
- Locations
- 🇺🇸
Bellevue Pediatric Associates, Bellevue, Pennsylvania, United States
🇺🇸Allegheny General Hospital, Pittsburgh, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.